Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1977 1
1981 2
1983 1
1984 6
1985 3
1986 2
1987 2
1988 4
1989 7
1990 4
1991 7
1992 8
1993 16
1994 5
1995 21
1996 16
1997 8
1998 36
1999 45
2000 63
2001 56
2002 79
2003 81
2004 100
2005 117
2006 116
2007 152
2008 186
2009 211
2010 219
2011 244
2012 337
2013 403
2014 535
2015 658
2016 670
2017 722
2018 902
2019 1156
2020 1223
2021 1247
2022 1245
2023 1286
2024 577

Text availability

Article attribute

Article type

Publication date

Search Results

11,028 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant Hepatobiliary Neoplasm"
Page 1
Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Ilyas SI, Gores GJ. Ilyas SI, et al. Gastroenterology. 2013 Dec;145(6):1215-29. doi: 10.1053/j.gastro.2013.10.013. Epub 2013 Oct 15. Gastroenterology. 2013. PMID: 24140396 Free PMC article. Review.
Cholangiocarcinomas (CCAs) are hepatobiliary cancers with features of cholangiocyte differentiation; they can be classified anatomically as intrahepatic CCA (iCCA), perihilar CCA (pCCA), or distal CCA. ...
Cholangiocarcinomas (CCAs) are hepatobiliary cancers with features of cholangiocyte differentiation; they can be classified anatomica …
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. McGuigan A, et al. World J Gastroenterol. 2018 Nov 21;24(43):4846-4861. doi: 10.3748/wjg.v24.i43.4846. World J Gastroenterol. 2018. PMID: 30487695 Free PMC article. Review.
This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further research in this understudied malignancy. Pancreatic adenocarcinoma is a lethal condition …
This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma risk, diagnostics, treatment and outcomes, while iden …
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
Mao J, Wang D, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, Li Y, Sun H, Xue J, Song Y, Zuo B, Zhang J, Bian J, Zhang T, Yang X, Zhang L, Sang X, Zhao H. Mao J, et al. J Immunother Cancer. 2021 Dec;9(12):e003334. doi: 10.1136/jitc-2021-003334. J Immunother Cancer. 2021. PMID: 34873013 Free PMC article.
RESULTS: In total, 65 patients with advanced hepatobiliary cancers receiving anti-PD-1 treatment were included in this study. ...CONCLUSIONS: We demonstrate that the gut microbiome is associated with the clinical response to anti-PD-1 immunotherapy in patients with hepa …
RESULTS: In total, 65 patients with advanced hepatobiliary cancers receiving anti-PD-1 treatment were included in this study. ...CONC …
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.
Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Fagiuoli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, Volpes R, Mariani L, Regalia E, Flores M, Droz Dit Busset M, Sposito C. Mazzaferro V, et al. Lancet Oncol. 2020 Jul;21(7):947-956. doi: 10.1016/S1470-2045(20)30224-2. Lancet Oncol. 2020. PMID: 32615109 Free article. Clinical Trial.
Analyses were by intention to treat. Organ allocation policy changed during the course of the study and restricted patient accrual to 4 years. This trial is registered with ClinicalTrials.gov, NCT01387503. ...
Analyses were by intention to treat. Organ allocation policy changed during the course of the study and restricted patient accrual to …
Epidemiology of cholangiocarcinoma.
Bergquist A, von Seth E. Bergquist A, et al. Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):221-32. doi: 10.1016/j.bpg.2015.02.003. Epub 2015 Feb 16. Best Pract Res Clin Gastroenterol. 2015. PMID: 25966423 Review.
CCA is the second most common primary liver tumour and accounts for approximately 10-15% of all hepatobiliary malignancies. The development of CCA is linked to a wide spectrum of conditions causing biliary inflammation, cholestasis and inflammation of the liver. ...
CCA is the second most common primary liver tumour and accounts for approximately 10-15% of all hepatobiliary malignancies. Th …
Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Vater LB, Lefebvre B, Turk A, Clasen SC. Vater LB, et al. Curr Oncol Rep. 2022 Jul;24(7):943-950. doi: 10.1007/s11912-022-01256-6. Epub 2022 Mar 26. Curr Oncol Rep. 2022. PMID: 35347593 Review.
PURPOSE OF REVIEW: Fluoropyrimidine (FDP) chemotherapy regimens used in the treatment of solid tumors such as breast, gastrointestinal, and hepatobiliary malignancies have led to significant survival benefits. ...
PURPOSE OF REVIEW: Fluoropyrimidine (FDP) chemotherapy regimens used in the treatment of solid tumors such as breast, gastrointestinal, and …
Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation.
Wang LY, Zheng SS. Wang LY, et al. J Zhejiang Univ Sci B. 2018 Jul;19(7):497-504. doi: 10.1631/jzus.B1700156. J Zhejiang Univ Sci B. 2018. PMID: 29971988 Free PMC article. Review.
To improve the survival rates of recipients after LT, identifying predictive factors for prognosis after LT and establishing a model assessing prognosis are very important to HCC patients. There has recently been a lot of clinical and basic research on recurr …
To improve the survival rates of recipients after LT, identifying predictive factors for prognosis after LT and establishing a …
Advances in post-operative prognostic models for hepatocellular carcinoma.
He Z, She X, Liu Z, Gao X, Lu LU, Huang J, Lu C, Lin Y, Liang R, Ye J. He Z, et al. J Zhejiang Univ Sci B. 2023 Mar 15;24(3):191-206. doi: 10.1631/jzus.B2200067. J Zhejiang Univ Sci B. 2023. PMID: 36915996 Free PMC article. Review.
Hepatocellular carcinoma (HCC) is one of the most common malignancies and a leading cause of cancer-related death worldwide. Surgery remains the primary and most successful therapy option for the treatment of early- and mid-stage HCCs, but the high heterogeneity of HCC ren …
Hepatocellular carcinoma (HCC) is one of the most common malignancies and a leading cause of cancer-related death worldwide. Surgery …
Gallbladder carcinoma: radiologic-pathologic correlation.
Levy AD, Murakata LA, Rohrmann CA Jr. Levy AD, et al. Radiographics. 2001 Mar-Apr;21(2):295-314; questionnaire, 549-55. doi: 10.1148/radiographics.21.2.g01mr16295. Radiographics. 2001. PMID: 11259693 Review.
Primary carcinoma of the gallbladder is an uncommon, aggressive malignancy that affects women more frequently than men. Older age groups are most often affected, and coexisting gallstones are present in the vast majority of cases. ...The radiologic differential diagnosis i …
Primary carcinoma of the gallbladder is an uncommon, aggressive malignancy that affects women more frequently than men. Older age gro …
Incidence and Prognosis of Biliary Tract and Gallbladder Cancers in a Belgian Academic Hospital.
Gilliaux Q, Faugeras L, Martinet JP, De Ronde T, Badaoui A, Bertrand C, Dili A, Delos M, Jamart J, Baily A, D'Hondt L. Gilliaux Q, et al. J Gastrointest Cancer. 2021 Sep;52(3):1003-1009. doi: 10.1007/s12029-020-00526-5. Epub 2020 Sep 28. J Gastrointest Cancer. 2021. PMID: 32984916
BACKGROUND: Biliary tract and gallbladder cancers are rare tumors with a poor prognosis (except the ampulla type). The evolution of hepatobiliary cancer incidence varies widely around the world. ...The independent prognostic factors of survival were age (p = …
BACKGROUND: Biliary tract and gallbladder cancers are rare tumors with a poor prognosis (except the ampulla type). The evolution of …
11,028 results
You have reached the last available page of results. Please see the User Guide for more information.